Rodman & Renshaw Initiates Coverage On Quantum BioPharma with Buy Rating, Announces Price Target of $8

Benzinga Newsdesk www.benzinga.com Neutral 51.1%

Neg 0% Neu 51.1% Pos 0%

Rodman & Renshaw analyst Michael King initiates coverage on Quantum BioPharma (NASDAQ:QNTM) with a Buy rating and announces Price Target of $8.